A Medscape commentary highlights a growing trend in which some patients are more hesitant about evidence-based procedures like colonoscopy while showing greater interest in unregulated peptide therapies, describing this as an “inversion of risk.” Using the example of a 50-year-old postmenopausal patient with iron deficiency anemia who was reluctant to undergo a colonoscopy but interested in peptide treatments, the article illustrates how patients may perceive established medical procedures as riskier than experimental compounds that lack robust clinical evidence.
The commentary contrasts the well-established safety, regulation, and clinical evidence supporting colonoscopy with the uncertainty surrounding many peptide therapies marketed for anti-aging, muscle repair, weight loss, and performance enhancement. While colonoscopy is performed using standardized protocols and remains the gold standard for colorectal cancer screening and the evaluation of conditions such as iron deficiency anemia, many peptides lack FDA approval, rigorous human clinical trials, consistent manufacturing standards, and long-term safety data. The article also highlights concerns about product purity, contamination, inaccurate dosing, and misleading marketing claims associated with peptides sold online.